Advance on the clinical application of adalimumab in ophthalmology

doi:10.3877/cma.j.issn.2095-2007.2022.06.011

Abstract

Abstract:

Adalimumab is a one of biological agents for injection. Its structure is characterized by humanized monoclonal antibody against human tumor necrosis factor (TNF). Adalimumab has been approved by the State Food and Drug Administration for the treatment of rheumatoid arthritis and ankylosing spondylitis. Non infectious uveitis was included in the indication in March 2020. Adalimumab is more and more widely used in clinical application. In this paper, the latest development of adalimumab in ophthalmic diseases was reviewed.

Key words: Adalimumab, Anti human tumor necrosis factor, Clinical application, Progress

Jiaxi Ma, Qianqian Mi, Yiren Zhou, Dan Wang. Advance on the clinical application of adalimumab in ophthalmology[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(06): 377-381.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2022.06.011

https://zhykyxzz.cma-cmc.com.cn/EN/Y2022/V12/I06/377

References 56

[1]	Wajant H, Henkler F, Scheurich P. The TNF－receptor－associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators[J]. Cell Signal, 2001, 13(6): 389－400.
[2]	Chen G, Goeddel DV. TNF－R1 signaling: a beautiful pathway[J]. Science, 2002, 296(5573): 1634－1635.
[3]	Sippy BD, Hofman FM, Wright AD, et al. Soluble tumor necrosis factor receptors are present in human vitreous and shed by retinal pigment epithelial cells[J]. Exp Eye Res, 1996, 63(3): 311－317.
[4]	Cunningham ET, Stalder A, Sanna PP, et al. Localization of tumor necrosis factor receptor messenger RNA in normal and herpes simplex virus－infected mouse eyes[J]. Invest Ophthalmol Vis Sci, 1997, 38(1): 9－15.
[5]	Yoshida M, Yoshimura N, Hangai M, et al. Interleukin－1alpha, interleukin－1 beta, and tumor necrosis factor gene expression in endotoxin－induced uveitis[J]. Invest Ophthalmol Vis Sci, 1994, 35(3): 1107－1113.
[6]	Michalova K, Lim L. Biologic agents in the management of inflammatory eye diseases[J]. Curr Allergy Asthma Rep, 2008, 8(4): 339－347.
[7]	张亚美，赵娟，高青华，等. 302例中重度类风湿关节炎患者接受阿达木单抗治疗后生存质量的调查研究[J]. 中国药物应用与监测，2015，1(2)：120－123.
[8]	Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis[J]. Drug Des Devel Ther, 2016, (10): 2997－3003.
[9]	Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review[J]. Pharmacol Ther, 2008, 117(2): 244－279.
[10]	Humira (adalimumab). prescribing information[M]. Illinois: AbbVie, Inc, 2016.
[11]	Mo JS, Matsukawa A, Ohkawara S, et al. Involvement of TNF alpha, IL－1 beta and IL－1 receptor antagonist in LPS－induced rabbit uveitis[J]. Exp Eye Res, 1998, 66(5): 547－557.
[12]	Martín－Varillas JL, Calvo－Río V, Beltrán E, et al. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behcet's Disease[J]. Ophthalmology, 2018, 125(9): 1444－1451.
[13]	Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel[J]. Am JOphthalmol, 2000, 130(4): 492－513.
[14]	Cervantes－Castaneda R, Jawed N, Foster C. Immunosuppressive therapy for noninfectious uveitis[J]. Retin Physician, 2007, 4(2): 30－38.
[15]	Becker MD, Smith JR, Max R, et al. Management of sight－threatening uveitis: newtherapeutic options[J]. Drugs, 2005, 65(4): 497－519.
[16]	Khairallah M, Accorinti M, Muccioli C, et al. Epidemiology of Behcet disease[J]. Ocul Immunol Inflamm, 2012, 20(5): 324－335.
[17]	Sakane T, Takeno M, Suzuki N, et al. Behcet's disease[J]. N Engl J Med, 1999, 341(17): 1284－1291.
[18]	Ueda A, Takeno M, Ishigatsubo Y. Adalimumab in the management of Behcet's disease[J]. Therapeutics and Clinical Risk Management, 2015, (11): 611－619.
[19]	Saurenmann RK, Levinn AV, Feldmn BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long－term follow－up study[J]. Arthritis Rheum, 2007, 56(2): 647－657.
[20]	Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta－analysis approach[J]. Rheumatology, 2013, 52(5): 825－831.
[21]	Van Gelder RN. Drug costs effectiveness, and kids in the crossfire: Adalimumab in Juvenile Idiopathic Arthritis－Associated Uveitis[J]. American Academy of Ophthalmology, 2019, 126(3): 425－427.
[22]	张中宇，何欣，王秀云，等. 强直性脊柱炎伴发葡萄膜炎的临床治疗与分析[J]. 哈尔滨医科大学学报，2012，46(5)：481－483.
[23]	Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open－label study[J]. Ann Rheum Dis, 2009, 68(5): 696－701.
[24]	Van Denderen JC, Visman IM, Nurmohamed MT, et al. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis[J]. Rheumatol, 2014, 41(9): 1843－1848.
[25]	Levy－Clarke G, Jabs DA, Read RW, et al. Expert Panel Recommendations for the Use of AntieTumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders[J]. American Academy of Ophthalmology, 2014, 121(3): 785－796.
[26]	Takeuchi M, Taguchi M, Sato T, et al. Association of High－Mobility Group Box－1 with Th cell－related cytokines in the vitreous of ocular sarcoidosis patients[J]. Invest Ophthalmol Vis Sci, 2017, 58(1): 528－537.
[27]	Dave N, Chevour P, Mahendradas P, et al. Increased aqueous humor CD4⁺/CD8⁺lymphocyte ratio in ocular sarcoidosis[J]. Ocular Immunol Inflamm, 2019, 27(7): 1033－1040.
[28]	Maruyama K, Inaba T, Tamada T, et al. Vitreous lavage fluid and bronchoalveolar lavage fluid have equal diagnostic value in sarcoidosis[J]. Medicine (Baltimore), 2016, 95(49): e5531.
[29]	Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis[J]. N Engl J Med, 2016, 375(10): 932－943.
[30]	Wouters CH, Maes A, Foley KP, et al. Blau syndrome, the prototypic auto－inflammatory granulomatous disease[J]. Pediatr Rheumatol Online J, 2014, 12: 33.
[31]	Miceli－Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome[J]. Nat Genet, 2001, 29(1): 19－20.
[32]	Jindal AK, Pilania RK, Suri D, et al. A young female with early onset arthritis, uveitis, hepatic, and renal granulomas: a clinical tryst with Blau syndrome over 20 yearsand case？based review[J]. Rheumatology International, 2021, 41(1): 173－181.
[33]	Sugita S, Takase H, Taguchi C, et al. Ocular infiltrating CD4⁺ T cells from patients with Vogt－Koyanagi－Harada disease recognize human melanocyte anti－gens[J]. Invest Ophthalmol Vis Sci, 2006, 47(6): 2547－2554.
[34]	Su E, Oza VS, Latkany P. A case of recalcitrant pediatric Vogt－Koyanagi－Harada disease successfully controlled with adalimumab[J]. Journal of the Formosan Medical Association, 2019, 118(5): 945－950.
[35]	Kim JB, Jeroudi A, Angeles－Han ST, et al. Adalimumab for Pediatric Sympathetic Ophthalmia[J]. JAMA Ophthalmology, 2014, 132(8): 1022－1024.
[36]	Soheilian M, Jabbarpourbonyadi M, Soheilian R, et al. Bilateral uveitis after phakic intraocular lens implantation and management with adalimumab[J]. J Cataract Refract Surg, 2012, 38(6): 1094－1096.
[37]	Di Girolamo N, Visvanathan K, Lloyd A, et al. Expression of TNF－alpha by human plasma cells in chronic inflammation[J]. Leukoc Biol, 1997, 61(6): 667－678.
[38]	Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis[J]. Oman J Ophthalmol, 2011, 4(3): 139－141.
[39]	Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab[J]. Clin Rheumatol, 2010, 29(5): 559－561.
[40]	Ragum A, Kolomeyer AM, Fang C, et al. Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors[J]. Ocul Immunol Inflamm, 2014, 22(6): 469－477.
[41]	Hernández－Garfella ML, Gracia－García A, Cervera－Taulet E, et al. Adalimumab for recurrent orbital myositis in Crohn's disease: Report of a case with a 3－year follow－up[J]. Journal of Crohn's and Colitis, 2011, 5(3): 265－266.
[42]	Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous gluco corticoids for Graves' orbitopathy: efficacy and morbidity[J]. Clin Endocrinol Metab, 2011, 96(2): 320－332.
[43]	Ayabe R, Rootman DB, Hwang CJ, et al. Adalimumab as Steroid－Sparing Treatment of Inflammatory－Stage Thyroid Eye Disease[J]. Ophthalmic Plast Reconstr Surg, 2014, 30(5): 415－419.
[44]	Talat L, Lightman S, Tomkins－Netzer O. Ischemic retinal vasculitis and its management[J]. Ophthalmol, 2014: 197675.
[45]	Fabiani C, Sota J, Rigante D, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis[J]. Clinical Rheumatology, 2018, 37(10): 2805－2809.
[46]	Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy[J]. Surv Ophthalmol, 2005, 50(6): 519－541.
[47]	Steeples LR, Spry P, Lee RWJ, et al. Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy[J]. Springer Science Business Media B．V, 2018, 38(3): 1357－1362.
[48]	Anglade E, McKeown CA, Robb RM. Brown's syndrome[J]. Int Ophthalmol Clin, 1992, 32(1): 63－70.
[49]	Lang M, Faraji N, Coffey M, et al. MRI of acquired Brown syndrome: a report of two cases[J]. Radiol Case Rep, 2017, 13(1): 92－95.
[50]	Kenawy N, Pilz DT, Watts P. Familial unilateral Brown syndrome[J]. Indian J Ophthalmol, 2008, 56(5): 430－434.
[51]	Michels KL, Kurup SP, Curran ML，et al. A case of acquired Brown syndrome treated with Adalimumab [J]. Journal of AAPOS, 2020, 24(3): 167－169.
[52]	殷路. 急性区域性隐匿性外层视网膜病变的研究进展[J]. 中华实验眼科杂志，2015，33(7) ：669－672.
[53]	Stockman M, Sys C, Balik I, et al. Adalimumab in the management of Acute Zonal Occult Outer Retinopathy: a case report [J]. Acta Ophthalmologica, 2018, 96(261): 120.
[54]	AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use: US prescribing information 2016[OL]. [2017－02－02] URL
[55]	AbbVie GK. AbbVie and Eisai obtain additional approval for new indication of fully human anti－TNF－a monoclonal antibody HUMIRA in the treatment of non－infectious uveitis 2016[OL]. [2017－02－02] URL
[56]	AbbVie Ltd. Humira (adalimumab): EU summary of product characteristics 2016[OL]. [2017－02－02] URL

Please choose a citation manager

Content to export